증권 기록 · 과거 분기 (아카이브)
JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
26추적 보유자
+1Δ 보유자
740.96M보유 주식 수
$113.15B보고 가치
+1신규 편입 포지션
−0청산
모멘텀 입력값 (비교 가능한 운용사):
보유자 폭 +4.0% ·
주식 흐름 +0.7% ·
순 신규 포지션 +3.8%
— 산식
광범위한 매집 — 더 많은 보유자에 걸쳐 주식 수 증가
모든 소유권 수치: 추적 대상 13F 운용사 한정, 보통주 포지션, 보고 기간 Q2 2025
시계열 보유 현황
| 분기 | 보유자 | Δ | 주식 수 | 보고 가치 | 신규 | 청산 |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +1 | 1.45B | $367.13B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | — | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | — |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | — | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | — |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | — | −2 |
| Q2 2024 | 21 | — | 161.11M | $23.53B | — | — |
보유 현황 · Q2 2025
| # | 운용사 | 주식 수 | Δ 주식 수 | 가치 | 비중 | 보유 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 2 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 3 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 4 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 5 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 6 | The Vanguard Group ✦ (패시브) | 237.05M | — | $36.21B | 0.6% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 12 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 13 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 14 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 15 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 16 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 17 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 18 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 19 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 20 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 21 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 22 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 23 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 24 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 25 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 26 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 27 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 28 | BlackRock ✦ (패시브) | 203.85M | — | $31.14B | 0.6% | n/c | 1 | SEC ↗ |
| 29 | State Street Global Advisors ✦ (패시브) | 132.80M | -0.7% | $20.28B | 0.8% | ▼ Trim | 3 | SEC ↗ |
| 30 | Geode Capital Management ✦ (패시브) | 60.61M | +2.1% | $9.23B | 0.6% | ▲ Add | 5 | SEC ↗ |
| 31 | Geode Capital Management ✦ (패시브) | 60.61M | +2.1% | $9.23B | 0.6% | ▲ Add | 5 | SEC ↗ |
| 32 | Norges Bank ✦ (패시브) | 31.93M | +3.6% | $4.88B | 0.6% | ▲ Add | 5 | SEC ↗ |
| 33 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 34 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 35 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 36 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 37 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 38 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 39 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 40 | Wellington Management ✦ | 24.88M | +9.8% | $3.80B | 0.7% | ▲ Add | 5 | SEC ↗ |
| 41 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 42 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 43 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 44 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 45 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 46 | Fidelity (FMR) ✦ | 13.42M | — | $2.05B | 0.1% | n/c | 1 | SEC ↗ |
| 47 | T. Rowe Price ✦ | 8.38M | -17.1% | $1.28B | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 48 | T. Rowe Price ✦ | 8.38M | -17.1% | $1.28B | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 49 | Fisher Asset Management ✦ | 8.27M | -5.0% | $1.26B | 0.5% | ▼ Trim | 5 | SEC ↗ |
| 50 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 51 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 52 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 53 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 54 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 55 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 56 | AQR Capital Management ✦ | 4.80M | -8.9% | $728.72M | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 57 | D. E. Shaw & Co. ✦ | 2.85M | +142.4% | $434.70M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 58 | D. E. Shaw & Co. ✦ | 2.85M | +142.4% | $434.70M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 59 | Arrowstreet Capital ✦ | 2.46M | -25.5% | $375.64M | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 60 | Bridgewater Associates ✦ | 2.28M | +667.8% | $348.66M | 1.4% | ▲ Add | 5 | SEC ↗ |
| 61 | Marshall Wace ✦ | 1.58M | +73.5% | $241.89M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 62 | Marshall Wace ✦ | 1.58M | +73.5% | $241.89M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 63 | Marshall Wace ✦ | 1.58M | +73.5% | $241.89M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 64 | Adage Capital Partners ✦ | 1.34M | +4.5% | $204.16M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 65 | Millennium Management ✦ | 1.05M | -16.1% | $160.80M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 66 | Renaissance Technologies ✦ | 883.19K | +336.0% | $134.91M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 67 | Markel Group ✦ | 610.80K | 0.0% | $93.30M | 0.8% | Held | 5 | SEC ↗ |
| 68 | Markel Group ✦ | 610.80K | 0.0% | $93.30M | 0.8% | Held | 5 | SEC ↗ |
| 69 | Point72 Asset Management ✦ | 583.76K | 신규 | $89.17M | 0.2% | New | 1 | SEC ↗ |
| 70 | Citadel Advisors ✦ | 557.44K | -16.1% | $85.15M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 71 | Citadel Advisors ✦ | 557.44K | -16.1% | $85.15M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 72 | Tweedy, Browne ✦ | 244.71K | -44.2% | $37.38M | 3.5% | ▼ Trim | 5 | SEC ↗ |
| 73 | Gotham Asset Management ✦ | 184.35K | +87.3% | $28.16M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 74 | Two Sigma Investments ✦ | 176.99K | +638.8% | $27.04M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 75 | GAMCO Investors ✦ | 86.58K | -0.1% | $13.23M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 76 | Fairfax Financial ✦ | 73.40K | 0.0% | $11.20M | 0.6% | Held | 5 | SEC ↗ |
| 77 | Dodge & Cox ✦ | 20.95K | -0.7% | $3.20M | 0.0% | ▼ Trim | 5 | SEC ↗ |
"해당 운용사 비중" = 해당 운용사의 신고된 13F 주식 가치 대비 포지션 비중 — 확신도 지표. ✦ = 선별 운용사.
신규 매수자
| Point72 Asset Management | $89.17M | 0.2% |
청산됨
| 이번 분기 추적된 청산 종목이 없습니다. |
전체 시장 맥락: 전체 13F 공시 기관 기준 (SEC 구조화 데이터, Q1 2026): 1 보유 기관, 136.10K 주식, $33,268 신고 기준. 이는 위의 추적 유니버스 수치와 다른 이전 기간으로, 두 수치는 절대 혼용되지 않습니다.
공동 보유 빈도 높음
이 증권의 추적 보유자들이 가장 많이 함께 보유하는 종목 — 기본적 관계가 아닌 공동 보유 건수 기준.
공개시장 매수 (P)
당사 커버리지 기간 내 공개시장 내부자 매수가 없습니다.
공개시장 매도 (S)
Aug 17
Taubert Jennifer L
Officer · 15.00K 주(sh) · $3.95M
Aug 13
Duato Joaquin
Officer, Director · 20.98K 주(sh) · $5.50M
Aug 13
Duato Joaquin
Officer, Director · 102.31K 주(sh) · $26.70M
부여, 행사 및 세금 원천징수는 매수 또는 매도로 집계하지 않습니다. 방법론
뉴스
Aug 24
US FDA expands approval for J&J's drug for rare blood disorder ↗
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a…
Reuters
출처: 파싱된 13F 보통주 포지션 기반 보유 현황(추적 유니버스, 변동 비교 세트); 내부자 행은 Form 3/4/5에서; 지분은 Schedule 13D/13G에서 수집; 모든 공시는 SEC EDGAR 원문으로 연결됩니다.
보고 기간: Q2 2025 ·
방법론 ·
API를 통해 조회